FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200546355> ?p ?o ?g. }

• W4200546355 abstract "Active surveillance (AS) is the reference standard treatment for the management of low risk prostate cancer (PCa). Accurate assessment of tumor aggressiveness guides recruitment to AS programs to avoid conservative treatment of intermediate and higher risk patients. Nevertheless, underestimating the disease risk may occur in some patients recruited, with biopsy upgrading and the concomitant potential for delayed treatment.To evaluate the accuracy of mpMRI and GPS for the prediction of biopsy upgrading during active surveillance (AS) management of prostate cancer (PCa).A retrospective analysis was performed on 144 patients recruited to AS from October 2013 to December 2020. Median follow was 4.8 (IQR 3.6, 6.3) years. Upgrading was defined as upgrading to biopsy grade group ≥2 on follow up biopsies. Cox proportional hazard regression was used to investigate the effect of PSA density (PSAD), baseline Prostate Imaging-Reporting and Data System (PI-RADS) v2.1 score and GPS on upgrading. Time-to-event outcome, defined as upgrading, was estimated using the Kaplan-Meier method with log-rank test.Overall rate of upgrading was 31.9% (n = 46). PSAD was higher in the patients who were upgraded (0.12 vs. 0.08 ng/ml2 , p = .005), while no significant difference was present for median GPS in the overall cohort (overall median GPS 21; 22 upgrading vs. 20 no upgrading, p = .2044). On univariable cox proportional hazard regression analysis, the factors associated with increased risk of biopsy upgrading were PSA (HR = 1.30, CI 1.16-1.47, p = <.0001), PSAD (HR = 1.08, CI 1.05-1.12, p = <.0001) and higher PI-RADS score (HR = 3.51, CI 1.56-7.91, p = .0024). On multivariable cox proportional hazard regression analysis, only PSAD (HR = 1.10, CI 1.06-1.14, p = <.001) and high PI-RADS score (HR = 4.11, CI 1.79-9.44, p = .0009) were associated with upgrading. A cox regression model combining these three clinical features (PSAD ≥0.15 ng/ml2 at baseline, PI-RADS Score and GPS) yielded a concordance index of 0.71 for the prediction of upgrading.In this study PSAD has higher accuracy over baseline PI-RADS score and GPS score for the prediction of PCa upgrading during AS. However, combined use of PSAD, GPS and PI-RADS Score yielded the highest predictive ability with a concordance index of 0.71." @default.
• W4200546355 created "2021-12-31" @default.
• W4200546355 creator A5009040855 @default.
• W4200546355 creator A5017103696 @default.
• W4200546355 creator A5022309971 @default.
• W4200546355 creator A5023611204 @default.
• W4200546355 creator A5029066570 @default.
• W4200546355 creator A5030791483 @default.
• W4200546355 creator A5043984769 @default.
• W4200546355 creator A5048742172 @default.
• W4200546355 creator A5052757074 @default.
• W4200546355 creator A5054214324 @default.
• W4200546355 creator A5068285584 @default.
• W4200546355 creator A5071632973 @default.
• W4200546355 creator A5073612543 @default.
• W4200546355 creator A5079763596 @default.
• W4200546355 creator A5090263966 @default.
• W4200546355 date "2021-12-20" @default.
• W4200546355 modified "2023-10-14" @default.
• W4200546355 title "Unified model involving genomics, magnetic resonance imaging and prostate‐specific antigen density outperforms individual co‐variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer" @default.
• W4200546355 cites W2131988302 @default.
• W4200546355 cites W2135546504 @default.
• W4200546355 cites W2150095882 @default.
• W4200546355 cites W2284433611 @default.
• W4200546355 cites W2475267864 @default.
• W4200546355 cites W2511949746 @default.
• W4200546355 cites W2512180612 @default.
• W4200546355 cites W2518676577 @default.
• W4200546355 cites W2577453388 @default.
• W4200546355 cites W2735211627 @default.
• W4200546355 cites W2763351477 @default.
• W4200546355 cites W2763709490 @default.
• W4200546355 cites W2770723187 @default.
• W4200546355 cites W2810729393 @default.
• W4200546355 cites W2885220860 @default.
• W4200546355 cites W2898746949 @default.
• W4200546355 cites W2905011711 @default.
• W4200546355 cites W2906542507 @default.
• W4200546355 cites W2939438597 @default.
• W4200546355 cites W2941047079 @default.
• W4200546355 cites W2941281880 @default.
• W4200546355 cites W2984399591 @default.
• W4200546355 cites W3009200944 @default.
• W4200546355 cites W3048873723 @default.
• W4200546355 cites W3090168712 @default.
• W4200546355 cites W3090551147 @default.
• W4200546355 cites W3092454626 @default.
• W4200546355 cites W3111361234 @default.
• W4200546355 cites W4200546355 @default.
• W4200546355 doi "https://doi.org/10.1002/cnr2.1492" @default.
• W4200546355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34931468" @default.
• W4200546355 hasPublicationYear "2021" @default.
• W4200546355 type Work @default.
• W4200546355 citedByCount "2" @default.
• W4200546355 countsByYear W42005463552021 @default.
• W4200546355 countsByYear W42005463552023 @default.
• W4200546355 crossrefType "journal-article" @default.
• W4200546355 hasAuthorship W4200546355A5009040855 @default.
• W4200546355 hasAuthorship W4200546355A5017103696 @default.
• W4200546355 hasAuthorship W4200546355A5022309971 @default.
• W4200546355 hasAuthorship W4200546355A5023611204 @default.
• W4200546355 hasAuthorship W4200546355A5029066570 @default.
• W4200546355 hasAuthorship W4200546355A5030791483 @default.
• W4200546355 hasAuthorship W4200546355A5043984769 @default.
• W4200546355 hasAuthorship W4200546355A5048742172 @default.
• W4200546355 hasAuthorship W4200546355A5052757074 @default.
• W4200546355 hasAuthorship W4200546355A5054214324 @default.
• W4200546355 hasAuthorship W4200546355A5068285584 @default.
• W4200546355 hasAuthorship W4200546355A5071632973 @default.
• W4200546355 hasAuthorship W4200546355A5073612543 @default.
• W4200546355 hasAuthorship W4200546355A5079763596 @default.
• W4200546355 hasAuthorship W4200546355A5090263966 @default.
• W4200546355 hasBestOaLocation W42005463551 @default.
• W4200546355 hasConcept C121608353 @default.
• W4200546355 hasConcept C126322002 @default.
• W4200546355 hasConcept C126894567 @default.
• W4200546355 hasConcept C143998085 @default.
• W4200546355 hasConcept C167135981 @default.
• W4200546355 hasConcept C207103383 @default.
• W4200546355 hasConcept C2775934546 @default.
• W4200546355 hasConcept C2776235491 @default.
• W4200546355 hasConcept C2779384505 @default.
• W4200546355 hasConcept C2780192828 @default.
• W4200546355 hasConcept C2781217009 @default.
• W4200546355 hasConcept C2781406297 @default.
• W4200546355 hasConcept C44249647 @default.
• W4200546355 hasConcept C50382708 @default.
• W4200546355 hasConcept C71924100 @default.
• W4200546355 hasConcept C72563966 @default.
• W4200546355 hasConceptScore W4200546355C121608353 @default.
• W4200546355 hasConceptScore W4200546355C126322002 @default.
• W4200546355 hasConceptScore W4200546355C126894567 @default.
• W4200546355 hasConceptScore W4200546355C143998085 @default.
• W4200546355 hasConceptScore W4200546355C167135981 @default.
• W4200546355 hasConceptScore W4200546355C207103383 @default.
• W4200546355 hasConceptScore W4200546355C2775934546 @default.
• W4200546355 hasConceptScore W4200546355C2776235491 @default.
• W4200546355 hasConceptScore W4200546355C2779384505 @default.
• W4200546355 hasConceptScore W4200546355C2780192828 @default.
• W4200546355 hasConceptScore W4200546355C2781217009 @default.

• next